Search Results - barbara+slusher

17 Results Sort By:
Intranasal Delivery of Testosterone Prodrugs to the CNS
Unmet NeedProstate cancer (PC) is the most common non-cutaneous malignancy in men with over 1.4 million new cases diagnosed globally in 2020 (see Wang 2022). Although disease confined to the prostate is highly curable, many men will be diagnosed with metastatic prostate cancer which is not curable but is treatable. The gold standard of care is androgen...
Published: 3/14/2025   |   Inventor(s): Rana Rais, Barbara Slusher, Mark Markowski, Arindom Pal
Keywords(s):  
Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Small Molecules
Small Molecule Neutral Sphingomyelinase 2 (nSMase2) Inhibitors
Unmet NeedNeutral sphingomyelinase 2 (nSMase2) is expressed in neurons and hydrolyzes sphingomyelin, producing the lipid ceramide, which functions in stress responses leading to apoptosis, cell growth arrest, and differentiation.  Increased levels of ceramides have been associated with many neurological disorders, including Alzheimer’s disease, multiple...
Published: 3/14/2025   |   Inventor(s): Takashi Tsukamoto, Niyada Hin, Ondrej Stepanek, Barbara Slusher, Camilo Rojas, Ajit Thomas
Keywords(s): Antagonists/Inhibitors, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules
Inhibition of nSMase for the Treatment of Human Immunodeficiency Virus Infection
Unmet NeedHuman immunodeficiency virus (HIV) is a retrovirus that negatively impacts the immune system, leading to immunosuppression and increased susceptibility to secondary, opportunistic infections and some cancers. It is estimated that 36.7 million people worldwide are currently living with HIV. Presently, HIV has no cure and requires life-long...
Published: 3/13/2025   |   Inventor(s): Norman Haughey, Barbara Slusher, Camilo Rojas
Keywords(s): Antagonists/Inhibitors, Disease Indication, HIV, Infectious Diseases, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases > HIV
Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases
Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...
Published: 3/13/2025   |   Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey
Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease
Prodrug for Immunological and Oncological Therapy
Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...
Published: 3/14/2025   |   Inventor(s): Barbara Slusher, Rana Rais, Franco D'alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian
Keywords(s): Blood Cancer, Cancers, Disease Indication, Inflammatory Disorders, Respiratory Infections, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Transplants
Category(s): Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Clinical and Disease Specializations > Transplantation, Technology Classifications > Therapeutic Modalities > Small Molecules
GCPII Inhibition for the Treatment of Sarcopenia and Aging
Unmet Need:Sarcopenia is the progressive loss of muscle mass and function, and is a natural part of the aging process. Age-related muscle loss and weakness can contribute to frailty and increase the likelihood of falls and fractures in older adults. Recent reports found that 5-13% of persons over the age of 65 years and >50% of people 80 years and...
Published: 3/14/2025   |   Inventor(s): Barbara Slusher, Carolyn Tallon
Keywords(s):  
Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Geriatrics
DOPA and Caffeic Acid Analogs as Novel GCPII Inhibitors
Unmet NeedGlutamate is the primary excitatory neurotransmitter in the human brain [1]. Excessive glutamate signaling can disrupt calcium homeostasis, leading to mitochondrial dysfunction, the overproduction of reactive oxygen species, and neuron loss via necrotic or apoptotic pathways [2]. This phenomenon, known as excitotoxicity, contributes to disease...
Published: 3/14/2025   |   Inventor(s): Barbara Slusher, Rana Rais, Takashi Tsukamoto
Keywords(s):  
Category(s): Clinical and Disease Specializations > Neurology, Technology Classifications, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules
Preventing Acute Kidney Injury Using JHU083
Unmet Need: It is estimated that 13.3 million people worldwide are affected by acute kidney injury (AKI) (see Bjornstad et. al). AKI is an especially prevalent condition in kidney transplant recipients, with one study showing that 35% of recipients had at least one episode of AKI (see Palmisiano et. al). These injury events lead to worsening kidney...
Published: 3/14/2025   |   Inventor(s): Hamid Rabb, Barbara Slusher, Jonathan Powell, Kyungho Lee, Elizabeth Thompson, Sanjeev Noel, Sepideh Gharaie
Keywords(s):  
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Nephrology
Methods to Treat Neurodegenerative Diseases
Unmet NeedAn estimated 930K people in the US are living with a neurodegenerative disease (Alzheimer’s and Parkinson’s are most common). However, current standard of care treatments mostly addresses symptoms of these diseases. To date no disease modifying or neuroprotective treatments are approved for Parkinson, and only 1 recently has been for Alzheimer’s...
Published: 3/14/2025   |   Inventor(s): Rana Rais, Barbara Slusher, Arindom Pal
Keywords(s):  
Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Multiple Sclerosis, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders
Discovery of 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases
Unmet NeedAlzheimer’s disease (AD) is the most common form of dementia, affecting approximately 5.7 million people in the United States in 2018. Yet, no cure exists for AD, and AD therapeutics presently on the market fail to treat the disease’s underlying causes. Recent studies in mice reveal that exosomes released from glial cells contribute to the...
Published: 3/14/2025   |   Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Norman Haughey, Marc Ferrer, Xin Hu
Keywords(s): Antagonists/Inhibitors, Cancers, CNS and Neurological Disorders, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules
1 2 
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum